BTK and primary central nervous system lymphoma: Identifying PCNSL as being of the MCD subtype, either by identifying a MYD88L265P mutation or a variant of CD79B, may have potential therapeutic implications, as tumours of this subtype are sensitive to treatment using BTK inhibitors.